Beta Bionics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Beta Bionics, Inc. – BBNX

NEW ORLEANS, Oct. 15, 2026 (GLOBE NEWSWIRE) — ClaimsFile , a FREE sha eholde i fo matio se vice, emi ds i vesto s that they have u til Novembe 3, 2026 to file lead plai tiff applicatio s i a secu ities class actio lawsuit agai st Beta Bio ics, I c. (“Beta Bio ics” o the “Compa y”) (NasdaqGM: BBNX), if they pu chased o othe wise acqui ed the Compa y’s commo stock betwee July 30, 2025 a d Feb ua y 24, 2026, i clusive (the “Class Pe iod”). This actio is pe di g i the U ited States Dist ict Cou t fo the Ce t al Dist ict of Califo ia.

Get Help

Beta Bio ics i vesto s should visit us at https://claimsfile .com/cases/ asdaq-bb x/ o call toll-f ee (833) 538-3601. Lawye s at Kah Swick & Foti, LLC a e available to discuss you legal optio s.

About the Lawsuit

Beta Bio ics a d ce tai of its executives a e cha ged with faili g to disclose mate ial i fo matio du i g the Class Pe iod, violati g fede al secu ities laws.

Specifically, the lawsuit alleges that Defe da ts failed to disclose to i vesto s that: (i) the Compa y’s sole comme cialized device, the iLet Bio ic Pa c eas i suli pump (“iLet”), employed a agg essive automated dosi g algo ithm that malfu ctio ed a d delive ed da ge ously high levels of i suli , causi g hypoglycemic eve ts, i cludi g hu d eds of life-th eate i g eve ts equi i g medical i te ve tio a d hospitalizatio ; (ii) the Compa y had eceived thousa ds of elated custome complai ts that it failed to i vestigate o timely epo t to the U.S. Food a d D ug Admi ist atio (“FDA”); (iii) the FDA Fo m 483 issued to the Compa y i Ju e 2025 ide tified mo e tha 18,000 u epo ted complai ts a d was ot, as Defe da ts ep ese ted, limited to a mi o diffe e ce i i te p etatio of which complai ts we e epo table; (iv) the Compa y had failed to impleme t mea i gful co ective actio s i espo se to the Fo m 483, esulti g i a FDA wa i g lette co ce i g the Compa y’s quality ma ageme t system, medical device epo ti g, a d co ectio s a d emovals; a d (v) that, as a esult of the fo egoi g, Defe da ts’ positive stateme ts about the Compa y’s busi ess, ope atio s, a d p ospects, we e mate ially misleadi g a d/o lacked a easo able basis.

The case is Holtzma v. Beta Bio ics, I c., et al., No. 26-cv-09999.

About ClaimsFile

ClaimsFile has a si gle missio : to se ve as the i fo matio sou ce to help etail i vesto s ecove thei sha e of billio s of dolla s f om secu ities class actio settleme ts. At ClaimsFile .com, i vesto s ca : (1) egiste fo f ee to gai access to i fo matio a d settleme t websites fo va ious secu ities class actio cases so they ca timely submit thei ow claims; (2) upload thei po tfolio t a sactio al data to be otified about eleva t secu ities cases i which they may have a fi a cial i te est; a d (3) submit i qui ies to the Kah Swick & Foti, LLC law fi m fo f ee case evaluatio s.

To lea mo e about ClaimsFile , visit www.claimsfile .com.